<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">37249286</PMID><DateCompleted><Year>2023</Year><Month>05</Month><Day>31</Day></DateCompleted><DateRevised><Year>2023</Year><Month>07</Month><Day>21</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">2050-4527</ISSN><JournalIssue CitedMedium="Internet"><Volume>11</Volume><Issue>5</Issue><PubDate><Year>2023</Year><Month>May</Month></PubDate></JournalIssue><Title>Immunity, inflammation and disease</Title><ISOAbbreviation>Immun Inflamm Dis</ISOAbbreviation></Journal><ArticleTitle>COVID-19 as a trigger of Guillain-Barr&#xe9; syndrome: A review of the molecular mechanism.</ArticleTitle><Pagination><StartPage>e875</StartPage><MedlinePgn>e875</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">e875</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1002/iid3.875</ELocationID><Abstract><AbstractText>Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) caused a pandemic with serious complications. After coronavirus disease 2019 (COVID-19), several post-acute COVID-19 syndromes (PACSs) and long-COVID sequels were reported. PACSs involve many organs, including the nervous, gustatory, and immune systems. One of the PACSs after SARS-CoV-2 infection and vaccination is Guillain-Barr&#xe9; syndrome (GBS). The incidence rate of GBS after SARS-CoV-2 infection or vaccination is low. However, the high prevalence of COVID-19 and severe complications of GBS, for example, autonomic dysfunction and respiratory failure, highlight the importance of post-COVID-19 GBS. It is while patients with simultaneous COVID-19 and GBS seem to have higher admission rates to the intensive care unit, and demyelination is more aggressive in post-COVID-19 GBS patients. SARS-CoV-2 can trigger GBS via several pathways like direct neurotropism and neurovirulence, microvascular dysfunction and oxidative stress, immune system disruption, molecular mimicry, and autoantibody production. Although there are few molecular studies on the molecular and cellular mechanisms of GBS occurrence after SARS-CoV-2 infection and vaccination, we aimed to discuss the possible pathomechanism of post-COVID-19 GBS by gathering the most recent molecular evidence.</AbstractText><CopyrightInformation>&#xa9; 2023 The Authors. Immunity, Inflammation and Disease published by John Wiley &amp; Sons Ltd.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Malekpour</LastName><ForeName>Mahdi</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0003-2784-0002</Identifier><AffiliationInfo><Affiliation>Student Research Committee, Shiraz University of Medical Sciences, Shiraz, Iran.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Transplant Research Center, Shiraz University of Medical Sciences, Shiraz, Iran.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Khanmohammadi</LastName><ForeName>Shaghayegh</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Network of Immunity in Infection, Malignancy and Autoimmunity (NIIMA), Universal Scientific Education and Research Network (USERN), Tehran, Iran.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Research Center for Immunodeficiencies, Children's Medical Center, Tehran University of Medical Sciences, Tehran, Iran.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Meybodi</LastName><ForeName>Mohammad Javad Entezari</ForeName><Initials>MJE</Initials><AffiliationInfo><Affiliation>Student Research Committee, Shiraz University of Medical Sciences, Shiraz, Iran.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Transplant Research Center, Shiraz University of Medical Sciences, Shiraz, Iran.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shekouh</LastName><ForeName>Dorsa</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Student Research Committee, Shiraz University of Medical Sciences, Shiraz, Iran.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rahmanian</LastName><ForeName>Mohammad Reza</ForeName><Initials>MR</Initials><AffiliationInfo><Affiliation>Student Research Committee, Shiraz University of Medical Sciences, Shiraz, Iran.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Transplant Research Center, Shiraz University of Medical Sciences, Shiraz, Iran.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kardeh</LastName><ForeName>Sina</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Central Clinical School, Monash University, Melbourne, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Azarpira</LastName><ForeName>Negar</ForeName><Initials>N</Initials><Identifier Source="ORCID">0000-0002-1518-1583</Identifier><AffiliationInfo><Affiliation>Transplant Research Center, Shiraz University of Medical Sciences, Shiraz, Iran.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Immun Inflamm Dis</MedlineTA><NlmUniqueID>101635460</NlmUniqueID><ISSNLinking>2050-4527</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="N">SARS-CoV-2</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020275" MajorTopicYN="Y">Guillain-Barre Syndrome</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000094024" MajorTopicYN="N">Post-Acute COVID-19 Syndrome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D058873" MajorTopicYN="N">Pandemics</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">GBS</Keyword><Keyword MajorTopicYN="N">Guillain-Barr&#xe9; syndrome</Keyword><Keyword MajorTopicYN="N">SARS-CoV-2</Keyword><Keyword MajorTopicYN="N">long COVID</Keyword><Keyword MajorTopicYN="N">postacute COVID-19 syndrome</Keyword></KeywordList><CoiStatement>The authors declare no conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="revised"><Year>2023</Year><Month>4</Month><Day>30</Day></PubMedPubDate><PubMedPubDate PubStatus="received"><Year>2023</Year><Month>3</Month><Day>20</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>5</Month><Day>3</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>5</Month><Day>31</Day><Hour>6</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>5</Month><Day>30</Day><Hour>13</Hour><Minute>7</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>5</Month><Day>30</Day><Hour>8</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2023</Year><Month>5</Month><Day>16</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37249286</ArticleId><ArticleId IdType="pmc">PMC10187022</ArticleId><ArticleId IdType="doi">10.1002/iid3.875</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Wu P, Hao X, Lau EHY, et al. Real&#x2010;time tentative assessment of the epidemiological characteristics of novel coronavirus infections in Wuhan, China, as at 22 January 2020. Euro Surveill. 2020;25(3):2000044.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6988272</ArticleId><ArticleId IdType="pubmed">31992388</ArticleId></ArticleIdList></Reference><Reference><Citation>
WHO
. Pneumonia of unknown cause&#x2014;China. WHO. https://www.who.int/csr/don/05-january-2020-pneumonia-of-unkown-cause-china/en/
</Citation></Reference><Reference><Citation>
WHO Director&#x2010;General's opening remarks at the media briefing on COVID&#x2010;19. WHO. Accessed 3 March 2020. https://www.who.int/director-general/speeches/detail/who-director-general-s-opening-remarks-at-the-media-briefing-on-covid-19---3-march-2020
</Citation></Reference><Reference><Citation>Richards F, Kodjamanova P, Chen X, et al. Economic burden of COVID&#x2010;19: a systematic review. Clinico Eco&#xa0;Outcomes Res. 2022;14:293&#x2010;307.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9060810</ArticleId><ArticleId IdType="pubmed">35509962</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen S, Prettner K, Kuhn M, Bloom DE. The economic burden of COVID&#x2010;19 in the United States: estimates and projections under an infection&#x2010;based herd immunity approach. J Econo Age. 2021;20:100328.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8186726</ArticleId><ArticleId IdType="pubmed">34123719</ArticleId></ArticleIdList></Reference><Reference><Citation>Channappanavar R, Zhao J, Perlman S. T cell&#x2010;mediated immune response to respiratory coronaviruses. Immunol Res. 2014;59(1):118&#x2010;128.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4125530</ArticleId><ArticleId IdType="pubmed">24845462</ArticleId></ArticleIdList></Reference><Reference><Citation>Tabary M, Khanmohammadi S, Araghi F, Dadkhahfar S, Tavangar SM. Pathologic features of COVID&#x2010;19: A concise review. Pathol Rese&#xa0;Pract. 2020;216(9):153097.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7334952</ArticleId><ArticleId IdType="pubmed">32825963</ArticleId></ArticleIdList></Reference><Reference><Citation>Vonck K, Garrez I, De Herdt V, et al. Neurological manifestations and neuro&#x2010;invasive mechanisms of the severe acute respiratory syndrome coronavirus type 2. Eur J Neurol. 2020;27(8):1578&#x2010;1587.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7276727</ArticleId><ArticleId IdType="pubmed">32416028</ArticleId></ArticleIdList></Reference><Reference><Citation>Monje M, Iwasaki A. The neurobiology of long COVID. Neuron. 2022;110:3484&#x2010;3496.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9537254</ArticleId><ArticleId IdType="pubmed">36288726</ArticleId></ArticleIdList></Reference><Reference><Citation>Rosenblum HG, Hadler SC, Moulia D, et al. Use of COVID&#x2010;19 vaccines after reports of adverse events among adult recipients of janssen (Johnson &amp; Johnson) and mRNA COVID&#x2010;19 vaccines (Pfizer&#x2010;BioNTech and Moderna): update from the advisory committee on immunization practices&#x2014;United States, July 2021. MMWR Morb Mortal Wkly Rep. 2021;70(32):1094&#x2010;1099.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8360272</ArticleId><ArticleId IdType="pubmed">34383735</ArticleId></ArticleIdList></Reference><Reference><Citation>Patone M, Handunnetthi L, Saatci D, et al. Neurological complications after first dose of COVID&#x2010;19 vaccines and SARS&#x2010;CoV&#x2010;2 infection. Nature Med. 2021;27(12):2144&#x2010;2153.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8629105</ArticleId><ArticleId IdType="pubmed">34697502</ArticleId></ArticleIdList></Reference><Reference><Citation>Rodriguez Y, Rojas M, Pacheco Y, et al. Guillain&#x2010;Barre syndrome, transverse myelitis and infectious diseases. Cell Mol Immunol. 2018;15(6):547&#x2010;562.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6079071</ArticleId><ArticleId IdType="pubmed">29375121</ArticleId></ArticleIdList></Reference><Reference><Citation>Willison HJ, Jacobs BC, van Doorn PA. Guillain&#x2010;Barr&#xe9; syndrome. Lancet. 2016;388(10045):717&#x2010;727.</Citation><ArticleIdList><ArticleId IdType="pubmed">26948435</ArticleId></ArticleIdList></Reference><Reference><Citation>Khanmohammadi S, Malekpour M, Jabbari P, Rezaei N. Genetic basis of Guillain&#x2010;Barre syndrome. J Neuroimmunol. 2021;358:577651.</Citation><ArticleIdList><ArticleId IdType="pubmed">34246981</ArticleId></ArticleIdList></Reference><Reference><Citation>McGrogan A, Madle GC, Seaman HE, de Vries CS. The epidemiology of Guillain&#x2010;Barr&#xe9; syndrome worldwide. Neuroepidemiology. 2009;32(2):150&#x2010;163.</Citation><ArticleIdList><ArticleId IdType="pubmed">19088488</ArticleId></ArticleIdList></Reference><Reference><Citation>Sejvar JJ, Baughman AL, Wise M, Morgan OW. Population incidence of Guillain&#x2010;Barr&#xe9; syndrome: a systematic review and Meta&#x2010;Analysis. Neuroepidemiology. 2011;36(2):123&#x2010;133.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5703046</ArticleId><ArticleId IdType="pubmed">21422765</ArticleId></ArticleIdList></Reference><Reference><Citation>Keddie S, Pakpoor J, Mousele C, et al. Epidemiological and cohort study finds no association between COVID&#x2010;19 and Guillain&#x2010;Barr&#xe9; syndrome. Brain. 2021;144(2):682&#x2010;693.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7799186</ArticleId><ArticleId IdType="pubmed">33313649</ArticleId></ArticleIdList></Reference><Reference><Citation>Cao&#x2010;Lormeau V&#x2010;M, Blake A, Mons S, et al. Guillain&#x2010;Barr&#xe9; syndrome outbreak associated with zika virus infection in French Polynesia: a case&#x2010;control study. Lancet. 2016;387(10027):1531&#x2010;1539.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5444521</ArticleId><ArticleId IdType="pubmed">26948433</ArticleId></ArticleIdList></Reference><Reference><Citation>Magira EE, Papaioakim M, Nachamkin I, et al. Differential distribution of HLA&#x2010;DQ beta/DR beta epitopes in the two forms of Guillain&#x2010;Barr&#xe9; syndrome, acute motor axonal neuropathy and acute inflammatory demyelinating polyneuropathy (AIDP): identification of DQ beta epitopes associated with susceptibility to and protection from AIDP. J&#xa0;Immunol. 2003;170(6):3074&#x2010;3080.</Citation><ArticleIdList><ArticleId IdType="pubmed">12626563</ArticleId></ArticleIdList></Reference><Reference><Citation>Rinaldi S. Coronavirus disease 2019 and the risk of Guillain&#x2013;Barr&#xe9; syndrome. Ann Neurol. 2021;89:846.</Citation><ArticleIdList><ArticleId IdType="pubmed">33394537</ArticleId></ArticleIdList></Reference><Reference><Citation>Vogrig A, Moritz CP, Camdessanch&#xe9; JP, et al. Unclear association between COVID&#x2010;19 and Guillain&#x2010;Barr&#xe9; syndrome. Brain. 2021;144(5):e45.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8083691</ArticleId><ArticleId IdType="pubmed">33755098</ArticleId></ArticleIdList></Reference><Reference><Citation>Filosto M, Cotti Piccinelli S, Gazzina S, et al. Guillain&#x2010;Barr&#xe9; syndrome and COVID&#x2010;19: an observational multicentre study from two Italian hotspot regions. J&#xa0;Neurol&#xa0;Neurosurg&#xa0;Psych. 2021;92(7):751&#x2010;756.</Citation><ArticleIdList><ArticleId IdType="pubmed">33158914</ArticleId></ArticleIdList></Reference><Reference><Citation>Rodr&#xed;guez Y, Rojas M, Beltr&#xe1;n S, et al. Autoimmune and autoinflammatory conditions after COVID&#x2010;19 vaccination. New case reports and updated literature review. J Autoimmun. 2022;132:102898.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9399140</ArticleId><ArticleId IdType="pubmed">36041291</ArticleId></ArticleIdList></Reference><Reference><Citation>Filosto M, Cotti Piccinelli S, Gazzina S, et al. Guillain&#x2010;Barr&#xe9; syndrome and COVID&#x2010;19: an observational multicentre study from two Italian hotspot regions. J Neurol Neurosurg Psychiatry. 2021;92(7):751&#x2010;756.</Citation><ArticleIdList><ArticleId IdType="pubmed">33158914</ArticleId></ArticleIdList></Reference><Reference><Citation>Newswanger DL, Warren CR. Guillain&#x2010;Barr&#xe9; syndrome. Am Fam Physician. 2004;69(10):2405&#x2010;2410.</Citation><ArticleIdList><ArticleId IdType="pubmed">15168961</ArticleId></ArticleIdList></Reference><Reference><Citation>Yuki N, Hartung H&#x2010;P. Guillain&#x2013;Barr&#xe9; syndrome. N Engl J Med. 2012;366(24):2294&#x2010;2304.</Citation><ArticleIdList><ArticleId IdType="pubmed">22694000</ArticleId></ArticleIdList></Reference><Reference><Citation>van Doorn PA, Ruts L, Jacobs BC. Clinical features, pathogenesis, and treatment of Guillain&#x2010;Barr&#xe9; syndrome. The Lancet Neurology. 2008;7(10):939&#x2010;950.</Citation><ArticleIdList><ArticleId IdType="pubmed">18848313</ArticleId></ArticleIdList></Reference><Reference><Citation>Hadden RD. Deterioration after Guillain&#x2013;Barr&#xe9; syndrome: recurrence, treatment&#x2010;related fluctuation or CIDP? J Neurol Neurosurg Psychiatry. 2009;80(1):3.</Citation><ArticleIdList><ArticleId IdType="pubmed">19091702</ArticleId></ArticleIdList></Reference><Reference><Citation>Novel Coronavirus (2019&#x2010;nCoV) technical guidance. Organization WH; 2021.</Citation></Reference><Reference><Citation>Wang F, Kream RM, Stefano GB. Long&#x2010;term respiratory and neurological sequelae of COVID&#x2010;19. Med Sci Monit. 2020;26:e928996.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7643287</ArticleId><ArticleId IdType="pubmed">33177481</ArticleId></ArticleIdList></Reference><Reference><Citation>Malik P, Patel K, Pinto C, et al. Post&#x2010;acute COVID&#x2010;19 syndrome (PCS) and health&#x2010;related quality of life (HRQoL)&#x2010;A systematic review and meta&#x2010;analysis. J Med Virol. 2022;94(1):253&#x2010;262.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8662132</ArticleId><ArticleId IdType="pubmed">34463956</ArticleId></ArticleIdList></Reference><Reference><Citation>Harapan BN, Yoo HJ. Neurological symptoms, manifestations, and complications associated with severe acute respiratory syndrome coronavirus 2 (SARS&#x2010;CoV&#x2010;2) and coronavirus disease 19 (COVID&#x2010;19). J Neurol. 2021;268(9):3059&#x2010;3071.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7826147</ArticleId><ArticleId IdType="pubmed">33486564</ArticleId></ArticleIdList></Reference><Reference><Citation>Premraj L, Kannapadi NV, Briggs J, et al. Mid and long&#x2010;term neurological and neuropsychiatric manifestations of post&#x2010;COVID&#x2010;19 syndrome: a meta&#x2010;analysis. J Neurol Sci. 2022;434:120162.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8798975</ArticleId><ArticleId IdType="pubmed">35121209</ArticleId></ArticleIdList></Reference><Reference><Citation>Walling AD, Dickson G. Guillain&#x2010;Barr&#xe9; syndrome. Am Fam Physician. 2013;87(3):191&#x2010;197.</Citation><ArticleIdList><ArticleId IdType="pubmed">23418763</ArticleId></ArticleIdList></Reference><Reference><Citation>Esposito S, Longo MR. Guillain&#x2013;Barr&#xe9; syndrome. Autoimmun Rev. 2017;16(1):96&#x2010;101.</Citation><ArticleIdList><ArticleId IdType="pubmed">27666816</ArticleId></ArticleIdList></Reference><Reference><Citation>Hughes RA, Cornblath DR. Guillain&#x2010;Barr&#xe9; syndrome. Lancet. 2005;366(9497):1653&#x2010;1666.</Citation><ArticleIdList><ArticleId IdType="pubmed">16271648</ArticleId></ArticleIdList></Reference><Reference><Citation>Toscano G, Palmerini F, Ravaglia S, et al. Guillain&#x2013;Barr&#xe9; syndrome associated with SARS&#x2010;CoV&#x2010;2. N Engl J Med. 2020;382(26):2574&#x2010;2576.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7182017</ArticleId><ArticleId IdType="pubmed">32302082</ArticleId></ArticleIdList></Reference><Reference><Citation>Aladawi M, Elfil M, Abu&#x2010;Esheh B, et al. Guillain barre syndrome as a complication of COVID&#x2010;19: a systematic review. Canadian J&#xa0;Neurol&#xa0;Sci 2022;49(1):38&#x2010;48.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8267336</ArticleId><ArticleId IdType="pubmed">33949300</ArticleId></ArticleIdList></Reference><Reference><Citation>Caress JB, Castoro RJ, Simmons Z, et al. COVID&#x2010;19&#x2013;associated Guillain&#x2010;Barr&#xe9; syndrome: the early pandemic experience. Muscle Nerve. 2020;62(4):485&#x2010;491.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7405390</ArticleId><ArticleId IdType="pubmed">32678460</ArticleId></ArticleIdList></Reference><Reference><Citation>Bauer L, Laksono BM, de Vrij FM, Kushner SA, Harschnitz O, van Riel D. The neuroinvasiveness, neurotropism, and neurovirulence of SARS&#x2010;CoV&#x2010;2. Trends Neurosci. 2022;15(5):358&#x2010;368.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8890977</ArticleId><ArticleId IdType="pubmed">35279295</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim JE, Heo JH, Kim H, et al. Neurological complications during treatment of Middle East respiratory syndrome. J&#xa0;Clin&#xa0;Neurol. 2017;13(3):227&#x2010;233.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5532318</ArticleId><ArticleId IdType="pubmed">28748673</ArticleId></ArticleIdList></Reference><Reference><Citation>Desforges M, Le Coupanec A, Brison E, Meessen&#x2010;Pinard M, Talbot PJ. Neuroinvasive and neurotropic human respiratory coronaviruses: potential neurovirulent agents in humans. Adv Exp Med Biol. 2014;807:75&#x2010;96.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7121612</ArticleId><ArticleId IdType="pubmed">24619619</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu J, Li Y, Liu Q, et al. SARS&#x2010;CoV&#x2010;2 cell tropism and multiorgan infection. Cell Discov. 2021;7(1):17.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7987126</ArticleId><ArticleId IdType="pubmed">33758165</ArticleId></ArticleIdList></Reference><Reference><Citation>Jackson CB, Farzan M, Chen B, Choe H. Mechanisms of SARS&#x2010;CoV&#x2010;2 entry into cells. Nat Rev Mol Cell Biol. 2022;23(1):3&#x2010;20.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8491763</ArticleId><ArticleId IdType="pubmed">34611326</ArticleId></ArticleIdList></Reference><Reference><Citation>Harrison AG, Lin T, Wang P. Mechanisms of SARS&#x2010;CoV&#x2010;2 transmission and pathogenesis. Trends Immunol. 2020;41(12):1100&#x2010;1115.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7556779</ArticleId><ArticleId IdType="pubmed">33132005</ArticleId></ArticleIdList></Reference><Reference><Citation>Zubair AS, McAlpine LS, Gardin T, Farhadian S, Kuruvilla DE, Spudich S. Neuropathogenesis and neurologic manifestations of the coronaviruses in the age of coronavirus disease 2019: a review. JAMA Neurol. 2020;77(8):1018&#x2010;1027.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7484225</ArticleId><ArticleId IdType="pubmed">32469387</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang L, Zhou L, Bao L, et al. SARS&#x2010;CoV&#x2010;2 crosses the blood&#x2010;brain barrier accompanied with basement membrane disruption without tight junctions alteration. Signal Transduct Target Ther. 2021;6(1):337.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8419672</ArticleId><ArticleId IdType="pubmed">34489403</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen R, Wang K, Yu J, et al. The spatial and Cell&#x2010;Type distribution of SARS&#x2010;CoV&#x2010;2 receptor ACE2 in the human and mouse brains. Front Neurol. 2021;11:573095.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7855591</ArticleId><ArticleId IdType="pubmed">33551947</ArticleId></ArticleIdList></Reference><Reference><Citation>Khan F, Sharma P, Pandey S, et al. COVID&#x2010;19&#x2010;associated Guillain&#x2010;Barre syndrome: postinfectious alone or neuroinvasive too? J Med Virol. 2021;93(10):6045&#x2010;6049.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8426929</ArticleId><ArticleId IdType="pubmed">34170552</ArticleId></ArticleIdList></Reference><Reference><Citation>Krasemann S, Haferkamp U, Pfefferle S, et al. The blood&#x2010;brain barrier is dysregulated in COVID&#x2010;19 and serves as a CNS entry route for SARS&#x2010;CoV&#x2010;2. Stem Cell Reports. 2022;17(2):307&#x2010;320.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8772030</ArticleId><ArticleId IdType="pubmed">35063125</ArticleId></ArticleIdList></Reference><Reference><Citation>Cacciola R, Gentilini Cacciola E, Vecchio V, Cacciola E. Cellular and molecular mechanisms in COVID&#x2010;19 coagulopathy: role of inflammation and endotheliopathy. J Thromb Thrombolysis. 2022;53(2):282&#x2010;290.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8536904</ArticleId><ArticleId IdType="pubmed">34687400</ArticleId></ArticleIdList></Reference><Reference><Citation>Eljilany I, Elzouki AN. D&#x2010;Dimer, fibrinogen, and IL&#x2010;6 in COVID&#x2010;19 patients with suspected venous thromboembolism: a narrative review. Vasc Health Risk Manag. 2020;16:455&#x2010;462.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7672709</ArticleId><ArticleId IdType="pubmed">33223833</ArticleId></ArticleIdList></Reference><Reference><Citation>Saheb Sharif&#x2010;Askari N, Saheb Sharif&#x2010;Askari F, Ahmed SBM, et al. Enhanced expression of autoantigens during SARS&#x2010;CoV&#x2010;2 viral infection. Front Immunol. 2021;12:686462.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8278821</ArticleId><ArticleId IdType="pubmed">34276672</ArticleId></ArticleIdList></Reference><Reference><Citation>Dunai C, Collie C, Michael BD. Immune&#x2010;Mediated mechanisms of COVID&#x2010;19 neuropathology. Front Neurol. 2022;13:882905.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9160362</ArticleId><ArticleId IdType="pubmed">35665037</ArticleId></ArticleIdList></Reference><Reference><Citation>Xiong X, Chi J, Gao Q. Prevalence and risk factors of thrombotic events on patients with COVID&#x2010;19: a systematic review and meta&#x2010;analysis. Thromb J. 2021;19(1):32.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8132033</ArticleId><ArticleId IdType="pubmed">34011381</ArticleId></ArticleIdList></Reference><Reference><Citation>Rovas A, Osiaevi I, Buscher K, et al. Microvascular dysfunction in COVID&#x2010;19: the MYSTIC study. Angiogenesis. 2021;24(1):145&#x2010;157.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7556767</ArticleId><ArticleId IdType="pubmed">33058027</ArticleId></ArticleIdList></Reference><Reference><Citation>Charfeddine S, Ibn Hadj Amor H, Jdidi J, et al. Long COVID 19 syndrome: is it related to microcirculation and endothelial dysfunction? insights from TUN&#x2010;EndCOV study. Front Cardiovasc Med. 2021;8:745758.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8670225</ArticleId><ArticleId IdType="pubmed">34917659</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu S&#x2010;W, Ilyas I, Weng J&#x2010;P. Endothelial dysfunction in COVID&#x2010;19: an overview of evidence, biomarkers, mechanisms and potential therapies. Acta Pharmacol Sin. 2022;44:695&#x2010; 709.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9574180</ArticleId><ArticleId IdType="pubmed">36253560</ArticleId></ArticleIdList></Reference><Reference><Citation>Kocivnik N, Velnar T. A review pertaining to SARS&#x2010;CoV&#x2010;2 and autoimmune diseases: what is the connection? Life. 2022;12(11):1918.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9698792</ArticleId><ArticleId IdType="pubmed">36431053</ArticleId></ArticleIdList></Reference><Reference><Citation>Yin J, Wang S, Liu Y, Chen J, Li D, Xu T. Coronary microvascular dysfunction pathophysiology in COVID&#x2010;19. Microcirculation. 2021;28(7):e12718.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8236988</ArticleId><ArticleId IdType="pubmed">34013612</ArticleId></ArticleIdList></Reference><Reference><Citation>Jin HY, Lee KA, Kim SY, Park JH, Baek HS, Park TS. A case of diabetic neuropathy combined with Guillain&#x2010;Barre syndrome. Korean J Intern Med. 2010;25(2):217&#x2010;220.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2880698</ArticleId><ArticleId IdType="pubmed">20526398</ArticleId></ArticleIdList></Reference><Reference><Citation>Afzal A, Javed R. Guillain&#x2010;Barr&#xe9; syndrome in a patient with diabetes mellitus. El Mednifico Journal. 2013;15(1):47&#x2010;50.</Citation></Reference><Reference><Citation>Kranc DA, Meurer D, Ryan MF. Guillan&#x2010;Barre syndrome in a patient with uncontrolled diabetes and severe peripheral neuropathy. Open J&#xa0;Emerg&#xa0;Med. 2018;06(2):27&#x2010;30.</Citation></Reference><Reference><Citation>Stirban A. Microvascular dysfunction in the context of diabetic neuropathy. Curr Diab Rep. 2014;14(11):541.</Citation><ArticleIdList><ArticleId IdType="pubmed">25189434</ArticleId></ArticleIdList></Reference><Reference><Citation>Mori I. Highlighting the &#x2018;blood&#x2010;nerve barrier&#x2019; in virology research. Acta Virol. 2018;62(1):28&#x2010;32.</Citation><ArticleIdList><ArticleId IdType="pubmed">29521100</ArticleId></ArticleIdList></Reference><Reference><Citation>Ubogu EE. Biology of the human blood&#x2010;nerve barrier in health and disease. Exp Neurol. 2020;328:113272.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7145763</ArticleId><ArticleId IdType="pubmed">32142802</ArticleId></ArticleIdList></Reference><Reference><Citation>Iwasaki A. Immune regulation of antibody access to neuronal tissues. Trends Mol Med. 2017;23(3):227&#x2010;245.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5626569</ArticleId><ArticleId IdType="pubmed">28185790</ArticleId></ArticleIdList></Reference><Reference><Citation>Hadden RDM, Gregson NA, Gold R, Smith KJ, Hughes RAC. Accumulation of immunoglobulin across the &#x2018;blood&#x2013;nerve barrier&#x2019; in spinal roots in adoptive transfer experimental autoimmune neuritis. Neuropathol Appl Neurobiol. 2002;28(6):489&#x2010;497.</Citation><ArticleIdList><ArticleId IdType="pubmed">12445165</ArticleId></ArticleIdList></Reference><Reference><Citation>Kanda T. Biology of the blood&#x2013;nerve barrier and its alteration in immune mediated neuropathies. J Neurol Neurosurg Psychiatry. 2013;84(2):208&#x2010;212.</Citation><ArticleIdList><ArticleId IdType="pubmed">23243216</ArticleId></ArticleIdList></Reference><Reference><Citation>Plomp JJ, Willison HJ. Pathophysiological actions of neuropathy&#x2010;related anti&#x2010;ganglioside antibodies at the neuromuscular junction. J Physiol. 2009;587(16):3979&#x2010;3999.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2756433</ArticleId><ArticleId IdType="pubmed">19564393</ArticleId></ArticleIdList></Reference><Reference><Citation>Hagen KM, Ousman SS. The neuroimmunology of Guillain&#x2010;Barr&#xe9; syndrome and the potential role of an aging immune system. Front Aging Neurosci. 2021;12:613628.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7873882</ArticleId><ArticleId IdType="pubmed">33584245</ArticleId></ArticleIdList></Reference><Reference><Citation>&#xdc;&#xe7;eyler N, Necula G, Wagemann E, Toyka KV, Sommer C. Endoneurial edema in sural nerve May indicate recent onset inflammatory neuropathy. Muscle Nerve. 2016;53(5):705&#x2010;710.</Citation><ArticleIdList><ArticleId IdType="pubmed">26439587</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen Y, Yang W, Chen F, Cui L. COVID&#x2010;19 and cognitive impairment: neuroinvasive and blood&#x2012;brain barrier dysfunction. J Neuroinflammation. 2022;19(1):222.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9450840</ArticleId><ArticleId IdType="pubmed">36071466</ArticleId></ArticleIdList></Reference><Reference><Citation>Knight JS, Caricchio R, Casanova JL, et al. The intersection of COVID&#x2010;19 and autoimmunity. J Clin Invest. 2021;131(24):e154886.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8670833</ArticleId><ArticleId IdType="pubmed">34710063</ArticleId></ArticleIdList></Reference><Reference><Citation>Ginanneschi F, Giannini F, Sicurelli F, et al. Clinical features and outcome of the Guillain&#x2013;Barre syndrome: a Single&#x2010;Center 11&#x2010;Year experience. Front Neurol. 2022;13:856091.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9289976</ArticleId><ArticleId IdType="pubmed">35860488</ArticleId></ArticleIdList></Reference><Reference><Citation>Kanda T, Yamawaki M, Mizusawa H. Sera from Guillain&#x2010;Barre patients enhance leakage in blood&#x2010;nerve barrier model. Neurology. 2003;60(2):301&#x2010;306.</Citation><ArticleIdList><ArticleId IdType="pubmed">12552049</ArticleId></ArticleIdList></Reference><Reference><Citation>Iijima N, Iwasaki A. Access of protective antiviral antibody to neuronal tissues requires CD4 T&#x2010;cell help. Nature. 2016;533(7604):552&#x2010;556.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4883597</ArticleId><ArticleId IdType="pubmed">27225131</ArticleId></ArticleIdList></Reference><Reference><Citation>Ubogu EE. Inflammatory neuropathies: pathology, molecular markers and targets for specific therapeutic intervention. Acta Neuropathol. 2015;130(4):445&#x2010;468.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4575885</ArticleId><ArticleId IdType="pubmed">26264608</ArticleId></ArticleIdList></Reference><Reference><Citation>Yosef N, Ubogu EE. &#x3b1;(M)&#x3b2;(2)&#x2010;integrin&#x2010;intercellular adhesion molecule&#x2010;1 interactions drive the flow&#x2010;dependent trafficking of Guillain&#x2010;Barr&#xe9; syndrome patient derived mononuclear leukocytes at the blood&#x2010;nerve barrier in vitro. J Cell Physiol. 2012;227(12):3857&#x2010;3875.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3414653</ArticleId><ArticleId IdType="pubmed">22552879</ArticleId></ArticleIdList></Reference><Reference><Citation>Dong C, Palladino SP, Helton ES, Ubogu EE. The pathogenic relevance of &#x3b1;(M)&#x2010;integrin in Guillain&#x2010;Barr&#xe9; syndrome. Acta Neuropathol. 2016;132(5):739&#x2010;752.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5074851</ArticleId><ArticleId IdType="pubmed">27460017</ArticleId></ArticleIdList></Reference><Reference><Citation>Greathouse KM, Palladino SP, Dong C, Helton ES, Ubogu EE. Modeling leukocyte trafficking at the human blood&#x2010;nerve barrier in vitro and in vivo geared towards targeted molecular therapies for peripheral neuroinflammation. J Neuroinflammation. 2016;13:3.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4702318</ArticleId><ArticleId IdType="pubmed">26732309</ArticleId></ArticleIdList></Reference><Reference><Citation>Iadecola C, Anrather J, Kamel H. Effects of COVID&#x2010;19 on the nervous system. Cell. 2020;183(1):16&#x2010;27.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7437501</ArticleId><ArticleId IdType="pubmed">32882182</ArticleId></ArticleIdList></Reference><Reference><Citation>Kronenberg M. Self&#x2010;tolerance and autoimmunity. Cell. 1991;65(4):537&#x2010;542.</Citation><ArticleIdList><ArticleId IdType="pubmed">2032283</ArticleId></ArticleIdList></Reference><Reference><Citation>Abani O, Abbas A, Abbas F, et al. Tocilizumab in patients admitted to hospital with COVID&#x2010;19 (RECOVERY): a randomised, controlled, open&#x2010;label, platform trial. Lancet. 2021;397(10285):1637&#x2010;1645.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8084355</ArticleId><ArticleId IdType="pubmed">33933206</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu B, Li M, Zhou Z, Guan X, Xiang Y. Can we use interleukin&#x2010;6 (IL&#x2010;6) blockade for coronavirus disease 2019 (COVID&#x2010;19)&#x2010;induced cytokine release syndrome (CRS)? J Autoimmun. 2020;111:102452.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7151347</ArticleId><ArticleId IdType="pubmed">32291137</ArticleId></ArticleIdList></Reference><Reference><Citation>Wampler Muskardin TL. Intravenous anakinra for macrophage activation syndrome May hold lessons for treatment of cytokine storm in the setting of coronavirus disease 2019. ACR Open Rheumatol. 2020;2(5):283&#x2010;285.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7231517</ArticleId><ArticleId IdType="pubmed">32267072</ArticleId></ArticleIdList></Reference><Reference><Citation>Giamarellos&#x2010;Bourboulis EJ, Netea MG, Rovina N, et al. Complex immune dysregulation in COVID&#x2010;19 patients with severe respiratory failure. Cell Host Microbe. 2020;27(6):992&#x2010;1000.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7172841</ArticleId><ArticleId IdType="pubmed">32320677</ArticleId></ArticleIdList></Reference><Reference><Citation>Yoshii F, Shinohara Y. Natural killer cells in patients with Guillain&#x2010;Barr&#xe9; syndrome. J Neurol Sci. 1998;157(2):175&#x2010;178.</Citation><ArticleIdList><ArticleId IdType="pubmed">9619642</ArticleId></ArticleIdList></Reference><Reference><Citation>Hussain FS, Eldeeb MA, Blackmore D, Siddiqi ZA. Guillain barr&#xe9; syndrome and COVID&#x2010;19: possible role of the cytokine storm. Autoimmun Rev. 2020;19(12):102681.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7577871</ArticleId><ArticleId IdType="pubmed">33099040</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang HL, Zheng XY, Zhu J. Th1/Th2/Th17/Treg cytokines in Guillain&#x2010;Barr&#xe9; syndrome and experimental autoimmune neuritis. Cytokine Growth Factor Rev. 2013;24(5):443&#x2010;453.</Citation><ArticleIdList><ArticleId IdType="pubmed">23791985</ArticleId></ArticleIdList></Reference><Reference><Citation>Hohnoki K, Inoue A, Koh CS. Elevated serum levels of IFN&#x2010;&#x3b3;, IL&#x2010;4 and TNF&#x2010;&#x3b1;/unelevated serum levels of IL&#x2010;10 in patients with demyelinating diseases during the acute stage. J Neuroimmunol. 1998;87(1&#x2010;2):27&#x2010;32.</Citation><ArticleIdList><ArticleId IdType="pubmed">9670842</ArticleId></ArticleIdList></Reference><Reference><Citation>Bodro M, Compta Y, Llans&#xf3; L, et al. Increased CSF levels of IL&#x2010;1&#x3b2;, IL&#x2010;6, and ACE in SARS&#x2010;CoV&#x2010;2&#x2010;associated encephalitis. Neurology. 2020;7(5):e821.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7357418</ArticleId><ArticleId IdType="pubmed">32611761</ArticleId></ArticleIdList></Reference><Reference><Citation>Pilotto A, Masciocchi S, Volonghi I, et al. Severe acute respiratory syndrome coronavirus 2 (SARS&#x2010;CoV&#x2010;2) encephalitis is a cytokine release syndrome: evidences from cerebrospinal fluid analyses. Clin Infect Dis. 2021;73(9):e3019&#x2010;e3026.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7799260</ArticleId><ArticleId IdType="pubmed">33395482</ArticleId></ArticleIdList></Reference><Reference><Citation>Kanda T. Biology of the blood&#x2010;nerve barrier and its alteration in immune mediated neuropathies. J&#xa0;Neurol&#xa0;Neurosurg&#xa0;Psych. 2013;84(2):208&#x2010;212.</Citation><ArticleIdList><ArticleId IdType="pubmed">23243216</ArticleId></ArticleIdList></Reference><Reference><Citation>Vahabi M, Ghazanfari T, Sepehrnia S. Molecular mimicry, hyperactive immune system, and SARS&#x2010;COV&#x2010;2 are three prerequisites of the autoimmune disease triangle following COVID&#x2010;19 infection. Int Immunopharmacol. 2022;112:109183.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9393178</ArticleId><ArticleId IdType="pubmed">36182877</ArticleId></ArticleIdList></Reference><Reference><Citation>Vorobjeva NV, Chernyak BV. NETosis: molecular mechanisms, role in physiology and pathology. Biochemistry (Moscow). 2020;85(10):1178&#x2010;1190.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7590568</ArticleId><ArticleId IdType="pubmed">33202203</ArticleId></ArticleIdList></Reference><Reference><Citation>Pascolini S, Vannini A, Deleonardi G, et al. COVID&#x2010;19 and immunological dysregulation: can autoantibodies be useful? Clin Transl Sci. 2021;14(2):502&#x2010;508.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7536986</ArticleId><ArticleId IdType="pubmed">32989903</ArticleId></ArticleIdList></Reference><Reference><Citation>Karaderi T, Bareke H, Kunter I, et al. Host genetics at the intersection of autoimmunity and COVID&#x2010;19: a potential key for heterogeneous COVID&#x2010;19 severity. Front Immunol. 2020;11:586111.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7783411</ArticleId><ArticleId IdType="pubmed">33414783</ArticleId></ArticleIdList></Reference><Reference><Citation>Lucchese G, Fl&#xf6;el A. SARS&#x2010;CoV&#x2010;2 and Guillain&#x2010;Barr&#xe9; syndrome: molecular mimicry with human heat shock proteins as potential pathogenic mechanism. Cell Stress Chaperones. 2020;25(5):731&#x2010;735.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7387880</ArticleId><ArticleId IdType="pubmed">32729001</ArticleId></ArticleIdList></Reference><Reference><Citation>Mobasheri L, Nasirpour MH, Masoumi E, Azarnaminy AF, Jafari M, Esmaeili S&#x2010;A. SARS&#x2010;CoV&#x2010;2 triggering autoimmune diseases. Cytokine. 2022;154:155873.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8979824</ArticleId><ArticleId IdType="pubmed">35461172</ArticleId></ArticleIdList></Reference><Reference><Citation>Felipe Cuspoca A, Isaac Estrada P, Velez&#x2010;van&#x2010;Meerbeke A. Molecular mimicry of SARS&#x2010;CoV&#x2010;2 spike protein in the nervous system: a bioinformatics approach. Comput Struct Biotechnol J. 2022;20:6041&#x2010;6054.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9605789</ArticleId><ArticleId IdType="pubmed">36317085</ArticleId></ArticleIdList></Reference><Reference><Citation>Wijdicks EF, Klein CJ, eds. Guillain&#x2010;barre syndrome. Mayo Clinic Proceedings. Elsevier; 2017.</Citation><ArticleIdList><ArticleId IdType="pubmed">28259232</ArticleId></ArticleIdList></Reference><Reference><Citation>Shahrizaila N, Lehmann HC, Kuwabara S. Guillain&#x2010;Barr&#xe9; syndrome. Lancet. 2021;397:1214&#x2010;1228.</Citation><ArticleIdList><ArticleId IdType="pubmed">33647239</ArticleId></ArticleIdList></Reference><Reference><Citation>Sekiguchi Y, Uncini A, Yuki N, et al. Antiganglioside antibodies are associated with axonal Guillain&#x2013;Barr&#xe9; syndrome: A Japanese&#x2013;Italian collaborative study. J Neurol Neurosurg Psychiatry. 2012;83(1):23&#x2010;28.</Citation><ArticleIdList><ArticleId IdType="pubmed">22010183</ArticleId></ArticleIdList></Reference><Reference><Citation>Lleix&#xe0; C, Mart&#xed;n&#x2010;Aguilar L, Pascual&#x2010;Go&#xf1;i E, et al. Autoantibody screening in Guillain&#x2013;Barr&#xe9; syndrome. J Neuroinflammation. 2021;18(1):251.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8559393</ArticleId><ArticleId IdType="pubmed">34719386</ArticleId></ArticleIdList></Reference><Reference><Citation>Jacobs BC, Koga M, van Rijs W, et al. Subclass IgG to motor gangliosides related to infection and clinical course in Guillain&#x2013;Barr&#xe9; syndrome. J Neuroimmunol. 2008;194(1):181&#x2010;190.</Citation><ArticleIdList><ArticleId IdType="pubmed">18178257</ArticleId></ArticleIdList></Reference><Reference><Citation>Tard C, Maurage CA, de Paula AM, et al. Anti&#x2010;pan&#x2010;neurofascin IgM in COVID&#x2010;19&#x2010;related Guillain&#x2010;Barr&#xe9; syndrome: evidence for a nodo&#x2010;paranodopathy. Neurophysiol Clin. 2020;50(5):397&#x2010;399.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7543699</ArticleId><ArticleId IdType="pubmed">33190687</ArticleId></ArticleIdList></Reference><Reference><Citation>Guilmot A, Maldonado Slootjes S, Bissay V, Dubuisson N, de Broglie C, Gille M. SARS&#x2010;CoV&#x2010;2&#x2010;associated Guillain&#x2010;Barr&#xe9; syndrome in four patients: what do we know about pathophysiology? Acta Neurol Belg. 2022;122(3):703&#x2010;707.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8412854</ArticleId><ArticleId IdType="pubmed">34476752</ArticleId></ArticleIdList></Reference><Reference><Citation>Tawakul AA, Al&#x2010;Doboke AW, Altayyar SA, Alsulami SA, Alfahmi AM, Nooh RT. Guillain&#x2010;Barr&#xe9; syndrome in the COVID&#x2010;19 pandemic. Neurol Int. 2021;14(1):34&#x2010;48.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8788454</ArticleId><ArticleId IdType="pubmed">35076589</ArticleId></ArticleIdList></Reference><Reference><Citation>Ahsan H, Ali A, Ali R. Oxygen free radicals and systemic autoimmunity. Clin Exp Immunol. 2003;131(3):398&#x2010;404.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1808645</ArticleId><ArticleId IdType="pubmed">12605691</ArticleId></ArticleIdList></Reference><Reference><Citation>Griffiths HR. Is the generation of neo&#x2010;antigenic determinants by free radicals central to the development of autoimmune rheumatoid disease? Autoimmun Rev. 2008;7(7):544&#x2010;549.</Citation><ArticleIdList><ArticleId IdType="pubmed">18625443</ArticleId></ArticleIdList></Reference><Reference><Citation>Ahsan H. 3&#x2010;Nitrotyrosine: a biomarker of nitrogen free radical species modified proteins in systemic autoimmunogenic conditions. Hum Immunol. 2013;74(10):1392&#x2010;1399.</Citation><ArticleIdList><ArticleId IdType="pubmed">23777924</ArticleId></ArticleIdList></Reference><Reference><Citation>Dogonadze SI, Ninua NG, Gordeziani MG, Kavlashvili MS, Sanikidze TV. [The role of oxidative stress in pathogenesis of GBS]. Georgian Med News. 2006;140:43&#x2010;47.</Citation><ArticleIdList><ArticleId IdType="pubmed">17179587</ArticleId></ArticleIdList></Reference><Reference><Citation>Ghabaee M, Jabedari B, Al&#x2010;E&#x2010;Eshagh N, Ghaffarpour M, Asadi F. Serum and cerebrospinal fluid antioxidant activity and lipid peroxidation in Guillain&#x2013;Barre syndrome and multiple sclerosis patients. Int J Neurosci. 2010;120(4):301&#x2010;304.</Citation><ArticleIdList><ArticleId IdType="pubmed">20374079</ArticleId></ArticleIdList></Reference><Reference><Citation>Hardy TA, Blum S, McCombe PA, Reddel SW. Guillain&#x2010;Barr&#xe9; syndrome: modern theories of etiology. Curr Allergy Asthma Rep. 2011;11(3):197&#x2010;204.</Citation><ArticleIdList><ArticleId IdType="pubmed">21451970</ArticleId></ArticleIdList></Reference><Reference><Citation>Wanschitz J. Distinct time pattern of complement activation and cytotoxic T cell response in Guillain&#x2010;Barre syndrome. Brain. 2003;126(9):2034&#x2010;2042.</Citation><ArticleIdList><ArticleId IdType="pubmed">12847075</ArticleId></ArticleIdList></Reference><Reference><Citation>Goodfellow JA, Willison HJ. Guillain&#x2013;Barr&#xe9; syndrome: a century of progress. Nat Rev Neurol. 2016;12(12):723&#x2010;731.</Citation><ArticleIdList><ArticleId IdType="pubmed">27857121</ArticleId></ArticleIdList></Reference><Reference><Citation>Willison HJ. The immunobiology of Guillain&#x2010;Barre syndromes. J Peripher Nerv Syst. 2005;10(2):94&#x2010;112.</Citation><ArticleIdList><ArticleId IdType="pubmed">15958123</ArticleId></ArticleIdList></Reference><Reference><Citation>Goodfellow JA, Willison HJ. Guillain&#x2010;Barr&#xe9; syndrome: a century of progress. Nat Rev Neurol. 2016;12(12):723&#x2010;731.</Citation><ArticleIdList><ArticleId IdType="pubmed">27857121</ArticleId></ArticleIdList></Reference><Reference><Citation>Susuki K, Rasband MN, Tohyama K, et al. Anti&#x2010;GM1 antibodies cause complement&#x2010;mediated disruption of sodium channel clusters in peripheral motor nerve fibers. J Neurosci. 2007;27(15):3956&#x2010;3967.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6672537</ArticleId><ArticleId IdType="pubmed">17428969</ArticleId></ArticleIdList></Reference><Reference><Citation>Ziganshin RH, Ivanova OM, Lomakin YA, et al. The pathogenesis of the demyelinating form of Guillain&#x2010;Barre syndrome (GBS): proteo&#x2010;peptidomic and immunological profiling of physiological fluids. Mol Cell Proteomics. 2016;15(7):2366&#x2010;2378.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4937510</ArticleId><ArticleId IdType="pubmed">27143409</ArticleId></ArticleIdList></Reference><Reference><Citation>Kariyawasam JC, Jayarajah U, Riza R, Abeysuriya V, Seneviratne SL. Gastrointestinal manifestations in COVID&#x2010;19. Trans R Soc Trop Med Hyg. 2021;115(12):1362&#x2010;1388.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7989191</ArticleId><ArticleId IdType="pubmed">33728439</ArticleId></ArticleIdList></Reference><Reference><Citation>Zuo T, Zhang F, Lui GCY, et al. Alterations in gut microbiota of patients with COVID&#x2010;19 during time of hospitalization. Gastroenterology. 2020;159(3):944&#x2010;955.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7237927</ArticleId><ArticleId IdType="pubmed">32442562</ArticleId></ArticleIdList></Reference><Reference><Citation>de Oliveira GLV. The gut microbiome in autoimmune diseases. Microbi&#xa0;Metabol&#xa0;Diag&#xa0;Ther Other Strat&#xa0;Appli. 2019;1:325&#x2010;332.</Citation></Reference><Reference><Citation>Kim D, Yoo S&#x2010;A, Kim W&#x2010;U. Gut microbiota in autoimmunity: potential for clinical applications. Arch Pharmacal Res. 2016;39(11):1565&#x2010;1576.</Citation><ArticleIdList><ArticleId IdType="pubmed">27444041</ArticleId></ArticleIdList></Reference><Reference><Citation>Lei H&#x2010;Y, Ding Y&#x2010;H, Nie K, et al. Potential effects of SARS&#x2010;CoV&#x2010;2 on the gastrointestinal tract and liver. Biomed Pharmacother. 2020;133:111064.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7700011</ArticleId><ArticleId IdType="pubmed">33378966</ArticleId></ArticleIdList></Reference><Reference><Citation>Bosco N, Noti M. The aging gut microbiome and its impact on host immunity. Genes &amp; Immunity. 2021;22:1&#x2010;15.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8054695</ArticleId><ArticleId IdType="pubmed">33875817</ArticleId></ArticleIdList></Reference><Reference><Citation>Khanmohammadi S, Kuchay MS. Toll&#x2010;like receptors and metabolic (dysfunction)&#x2010;associated fatty liver disease. Pharmacol Res. 2022;185:106507.</Citation><ArticleIdList><ArticleId IdType="pubmed">36252773</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu HJ, Wu E. The role of gut microbiota in immune homeostasis and autoimmunity. Gut Microbes. 2012;3(1):4&#x2010;14.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3337124</ArticleId><ArticleId IdType="pubmed">22356853</ArticleId></ArticleIdList></Reference><Reference><Citation>Ivanov II, Honda K. Intestinal commensal microbes as immune modulators. Cell Host Microbe. 2012;12(4):496&#x2010;508.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3516493</ArticleId><ArticleId IdType="pubmed">23084918</ArticleId></ArticleIdList></Reference><Reference><Citation>Hilpert K, Mikut R. Is there a connection between gut microbiome dysbiosis occurring in COVID&#x2010;19 patients and Post&#x2010;COVID&#x2010;19 symptoms? Front Microbiol. 2021;12:732838.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8485028</ArticleId><ArticleId IdType="pubmed">34603261</ArticleId></ArticleIdList></Reference><Reference><Citation>Katz&#x2010;Agranov N, Zandman&#x2010;Goddard G. Autoimmunity and COVID&#x2010;19 &#x2010; the microbiotal connection. Autoimmun Rev. 2021;20(8):102865.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8189735</ArticleId><ArticleId IdType="pubmed">34118455</ArticleId></ArticleIdList></Reference><Reference><Citation>Saxena A. Probiotics as a potential alternative for relieving peripheral neuropathies: a case for Guillain&#x2010;Barr&#xe9; syndrome. Front Microbiol. 2015;6:1497.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4703756</ArticleId><ArticleId IdType="pubmed">26779152</ArticleId></ArticleIdList></Reference><Reference><Citation>Cooney J, Appiahene P, Findlay R, et al. COVID&#x2010;19 infection causing residual gastrointestinal symptoms&#x2014;a single UK centre case series. Clin Med. 2022;22(2):181&#x2010;183.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8966828</ArticleId><ArticleId IdType="pubmed">35105680</ArticleId></ArticleIdList></Reference><Reference><Citation>Du M, Cai G, Chen F, Christiani DC, Zhang Z, Wang M. Multiomics evaluation of gastrointestinal and other clinical characteristics of COVID&#x2010;19. Gastroenterology. 2020;158(8):2298&#x2010;2301.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7270476</ArticleId><ArticleId IdType="pubmed">32234303</ArticleId></ArticleIdList></Reference><Reference><Citation>Xiao F, Tang M, Zheng X, Liu Y, Li X, Shan H. Evidence for gastrointestinal infection of SARS&#x2010;CoV&#x2010;2. Gastroenterology. 2020;158(6):1831&#x2010;1833.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7130181</ArticleId><ArticleId IdType="pubmed">32142773</ArticleId></ArticleIdList></Reference><Reference><Citation>Sedano MJ, Calleja J, Canga E, Berciano J. Guillain&#x2010;Barr&#xe9; syndrome in cantabria, Spain. An epidemiological and clinical study. Acta Neurol Scand. 1994;89(4):287&#x2010;292.</Citation><ArticleIdList><ArticleId IdType="pubmed">8042448</ArticleId></ArticleIdList></Reference><Reference><Citation>Van Koningsveld R, Rico R, Gerstenbluth I, et al. Gastroenteritis&#x2010;associated Guillain&#x2013;Barre syndrome on the Caribbean island Curacao. Neurology. 2001;56(11):1467&#x2010;1472.</Citation><ArticleIdList><ArticleId IdType="pubmed">11402102</ArticleId></ArticleIdList></Reference><Reference><Citation>Mattos&#x2010;Silva P, Felix NS, Silva PL, et al. Pros and cons of corticosteroid therapy for COVID&#x2010;19 patients. Respir Physiol Neurobiol. 2020;280:103492.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7351052</ArticleId><ArticleId IdType="pubmed">32659271</ArticleId></ArticleIdList></Reference><Reference><Citation>Singh AK, Singh R, Joshi SR, Misra A. Mucormycosis in COVID&#x2010;19: a systematic review of cases reported worldwide and in India. Diab Metab Syndr. 2021;15(4):102146.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8137376</ArticleId><ArticleId IdType="pubmed">34192610</ArticleId></ArticleIdList></Reference><Reference><Citation>Nagalli S, Kikkeri NS. Mucormycosis in COVID&#x2010;19: a systematic review of literature. Infez Med. 2021;29(4):504&#x2010;512.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8805463</ArticleId><ArticleId IdType="pubmed">35146358</ArticleId></ArticleIdList></Reference><Reference><Citation>Maccario M, Tarantino A, Nobile&#x2010;Orazio E, Ponticelli C. Campylobacter jejuni bacteremia and Guillain&#x2010;Barr&#xe9; syndrome in a renal transplant recipient. Transpl Int. 1998;11(6):439&#x2010;442.</Citation><ArticleIdList><ArticleId IdType="pubmed">9870273</ArticleId></ArticleIdList></Reference><Reference><Citation>Ostman C, Chacko B. Guillain&#x2010;Barr&#xe9; syndrome post renal transplant: a systematic review. Tranpl Infect Dis. 2019;21(1):e13021.</Citation><ArticleIdList><ArticleId IdType="pubmed">30403433</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang L, Arrington S, Keung Y&#x2010;K. Guillain&#x2010;Barr&#xe9; syndrome after transplantation. Leuk Lymphoma. 2008;49(2):291&#x2010;297.</Citation><ArticleIdList><ArticleId IdType="pubmed">18231916</ArticleId></ArticleIdList></Reference><Reference><Citation>Hern&#xe1;ndez&#x2010;Boluda JC, Lis MJ, Goterris R, et al. Guillain&#x2013;Barr&#xe9; syndrome associated with cytomegalovirus infection after allogeneic hematopoietic stem cell transplantation. Tranpl Infect Dis. 2005;7(2):93&#x2010;96.</Citation><ArticleIdList><ArticleId IdType="pubmed">16150099</ArticleId></ArticleIdList></Reference><Reference><Citation>Finsterer J, Scorza FA, Scorza CA, Fiorini AC. Peripheral neuropathy in COVID&#x2010;19 is due to immune&#x2010;mechanisms, pre&#x2010;existing risk factors, anti&#x2010;viral drugs, or bedding in the intensive care unit. Arq Neuropsiquiatr. 2021;79(10):924&#x2010;928.</Citation><ArticleIdList><ArticleId IdType="pubmed">34287509</ArticleId></ArticleIdList></Reference><Reference><Citation>Awong IE, Dandurand KR, Keeys CA, Maung&#x2010;Gyi FAK. Drug&#x2010;associated Guillain&#x2010;Barr&#xe9; syndrome: a literature review. Ann&#xa0;Pharmacother. 1996;30(2):173&#x2010;180.</Citation><ArticleIdList><ArticleId IdType="pubmed">8835052</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang W, Zhang W, Zhang J, He J, Zhu F. Distribution of HLA allele frequencies in 82 Chinese individuals with coronavirus disease&#x2010;2019 (COVID&#x2010;19). Hla. 2020;96(2):194&#x2010;196.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7276866</ArticleId><ArticleId IdType="pubmed">32424945</ArticleId></ArticleIdList></Reference><Reference><Citation>Yu X, Ho K, Shen Z, et al. The association of human leukocyte antigen and COVID&#x2010;19 in Southern China. Open Forum Infect Dis. 2021;8(9):ofab410.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8436377</ArticleId><ArticleId IdType="pubmed">34552996</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang Y, Guga S, Wu K, et al. COVID&#x2010;19 and systemic lupus erythematosus genetics: a balance between autoimmune disease risk and protection against infection. PLoS Genet. 2022;18(11):e1010253.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9632821</ArticleId><ArticleId IdType="pubmed">36327221</ArticleId></ArticleIdList></Reference><Reference><Citation>Gigli GL, Vogrig A, Nilo A, et al. HLA and immunological features of SARS&#x2010;CoV&#x2010;2&#x2010;induced Guillain&#x2010;Barr&#xe9; syndrome. Neurol Sci. 2020;41(12):3391&#x2010;3394.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7530349</ArticleId><ArticleId IdType="pubmed">33006723</ArticleId></ArticleIdList></Reference><Reference><Citation>
Nordquist HJR. Biochemistry, HLA antigens 2022. Accessed April 28, 2022.&#xa0;https://www.ncbi.nlm.nih.gov/books/NBK546662/
</Citation></Reference><Reference><Citation>Crux NB, Elahi S. Human leukocyte antigen (HLA) and immune regulation: how do classical and Non&#x2010;Classical HLA alleles modulate immune response to human immunodeficiency virus and hepatitis C virus infections? Front Immunol. 2017;8:832.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5513977</ArticleId><ArticleId IdType="pubmed">28769934</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang X, Tan Y, Ling Y, et al. Viral and host factors related to the clinical outcome of COVID&#x2010;19. Nature. 2020;583(7816):437&#x2010;440.</Citation><ArticleIdList><ArticleId IdType="pubmed">32434211</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang Y&#x2010;J, Kao K&#x2010;P, Lin K&#x2010;P. Recurrent polyradiculoneuropathy and PMP22 defects. J&#xa0;Chinese Med&#xa0;Assoc. 2005;68(11):513&#x2010;516.</Citation><ArticleIdList><ArticleId IdType="pubmed">16323394</ArticleId></ArticleIdList></Reference><Reference><Citation>Francis AI, Ghany S, Gilkes T, Umakanthan S. Review of COVID&#x2010;19 vaccine subtypes, efficacy and geographical distributions. Postgrad Med J. 2022;98(1159):389&#x2010;394.</Citation><ArticleIdList><ArticleId IdType="pubmed">37066438</ArticleId></ArticleIdList></Reference><Reference><Citation>Schonberger LB, Bregman DJ, Sullivan&#x2010;Bolyai JZ, et al. Guillain&#x2010;Barre syndrome following vaccination in The National influenza immunization program, United States, 1976&#x2013;1977. Am J Epidemiol. 1979;110(2):105&#x2010;123.</Citation><ArticleIdList><ArticleId IdType="pubmed">463869</ArticleId></ArticleIdList></Reference><Reference><Citation>Centers for Disease Control and Prevention (CDC) CfDCaP . Update: guillain&#x2010;Barr&#xe9; syndrome among recipients of menactra meningococcal conjugate vaccine&#x2013;United States, June 2005&#x2013;September 2006. MMWR Morb Mortal Wkly Rep. 2006;55(41):1120&#x2010;1124.</Citation><ArticleIdList><ArticleId IdType="pubmed">17060898</ArticleId></ArticleIdList></Reference><Reference><Citation>Khamaisi M, Shoenfeld Y, Orbach H. Guillain&#x2010;Barr&#xe9; syndrome following hepatitis B vaccination. Clin Exp Rheumatol. 2004;22(6):767&#x2010;770.</Citation><ArticleIdList><ArticleId IdType="pubmed">15638054</ArticleId></ArticleIdList></Reference><Reference><Citation>Kinnunen E, F&#xe4;rkkil&#xe4; M, Hovi T, Juntunen J, Weckstr&#xf6;m P. Incidence of Guillain&#x2010;Barr&#xe9; syndrome during a nationwide oral poliovirus vaccine campaign. Neurology. 1989;39(8):1034.</Citation><ArticleIdList><ArticleId IdType="pubmed">2788248</ArticleId></ArticleIdList></Reference><Reference><Citation>Souayah N, Michas&#x2010;Martin PA, Nasar A, et al. Guillain&#x2010;Barr&#xe9; syndrome after gardasil vaccination: data from vaccine adverse event reporting system 2006&#x2013;2009. Vaccine. 2011;29(5):886&#x2010;889.</Citation><ArticleIdList><ArticleId IdType="pubmed">20869467</ArticleId></ArticleIdList></Reference><Reference><Citation>Wajih Ullah M, Qaseem A, Amray A. Post vaccination guillain barre syndrome: a case report. Cureus. 2018;10(4):e2511.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6010361</ArticleId><ArticleId IdType="pubmed">29930889</ArticleId></ArticleIdList></Reference><Reference><Citation>Haber P, Sejvar J, Mikaeloff Y, DeStefano F. Vaccines and Guillain&#x2010;Barr&#xe9; syndrome. Drug Saf. 2009;32(4):309&#x2010;323.</Citation><ArticleIdList><ArticleId IdType="pubmed">19388722</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen Y, Zhang J, Chu X, Xu Y, Ma F. Vaccines and the risk of Guillain&#x2010;Barr&#xe9; syndrome. Eur J Epidemiol. 2020;35(4):363&#x2010;370.</Citation><ArticleIdList><ArticleId IdType="pubmed">31858323</ArticleId></ArticleIdList></Reference><Reference><Citation>Garc&#xed;a&#x2010;Grimshaw M, Michel&#x2010;Ch&#xe1;vez A, Vera&#x2010;Zertuche JM, et al. Guillain&#x2010;Barr&#xe9; syndrome is infrequent among recipients of the BNT162b2 mRNA COVID&#x2010;19 vaccine. Clin Immunol. 2021;230:108818.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8332675</ArticleId><ArticleId IdType="pubmed">34358692</ArticleId></ArticleIdList></Reference><Reference><Citation>Hanson KE, Goddard K, Lewis N, et al. Incidence of Guillain&#x2010;Barr&#xe9; syndrome after COVID&#x2010;19 vaccination in the vaccine safety datalink. JAMA Netw Open. 2022;5(4):e228879.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9044108</ArticleId><ArticleId IdType="pubmed">35471572</ArticleId></ArticleIdList></Reference><Reference><Citation>Keh RYS, Scanlon S, Datta&#x2010;Nemdharry P, et al. COVID&#x2010;19 vaccination and Guillain&#x2010;Barr&#xe9; syndrome: analyses using The National immunoglobulin database. Brain. 2022;146:739&#x2010;748.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8903477</ArticleId><ArticleId IdType="pubmed">35180300</ArticleId></ArticleIdList></Reference><Reference><Citation>Woo EJ, Mba&#x2010;Jonas A, Dimova RB, Alimchandani M, Zinderman CE, Nair N. Association of receipt of the Ad26. COV2. S COVID&#x2010;19 vaccine with presumptive Guillain&#x2010;Barr&#xe9; syndrome, February&#x2010;July 2021. JAMA. 2021;326(16):1606&#x2010;1613.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8498927</ArticleId><ArticleId IdType="pubmed">34617967</ArticleId></ArticleIdList></Reference><Reference><Citation>Atzenhoffer M, Auffret M, Pegat A, et al. Guillain&#x2010;Barr&#xe9; syndrome associated with COVID&#x2010;19 vaccines: a perspective from spontaneous report data. Clin Drug Invest. 2022;42(7):581&#x2010;592.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9177406</ArticleId><ArticleId IdType="pubmed">35676452</ArticleId></ArticleIdList></Reference><Reference><Citation>Frontera JA, Tamborska AA, Doheim MF, et al. Neurological events reported after COVID&#x2010;19 vaccines: an analysis of vaccine adverse event reporting system. Ann Neurol. 2022;91(6):756&#x2010;771.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9082459</ArticleId><ArticleId IdType="pubmed">35233819</ArticleId></ArticleIdList></Reference><Reference><Citation>Walker JL, Schultze A, Tazare J, et al. Safety of COVID&#x2010;19 vaccination and acute neurological events: a self&#x2010;controlled case series in England using the OpenSAFELY platform. Vaccine. 2022;40(32):4479&#x2010;4487.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9170533</ArticleId><ArticleId IdType="pubmed">35715350</ArticleId></ArticleIdList></Reference><Reference><Citation>Shasha D, Bareket R, Sikron FH, et al. Real&#x2010;world safety data for the Pfizer BNT162b2 SARS&#x2010;CoV&#x2010;2 vaccine: historical cohort study. Clin Microbiol Infect. 2022;28(1):130&#x2010;134.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8479307</ArticleId><ArticleId IdType="pubmed">34592420</ArticleId></ArticleIdList></Reference><Reference><Citation>Jaffry M, Mostafa F, Mandava K, et al. No significant increase in Guillain&#x2010;Barr&#xe9; syndrome after COVID&#x2010;19 vaccination in adults: a vaccine adverse event reporting system study. Vaccine. 2022;40(40):5791&#x2010;5797.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9393181</ArticleId><ArticleId IdType="pubmed">36055875</ArticleId></ArticleIdList></Reference><Reference><Citation>Li X, Ravent&#xf3;s B, Roel E, et al. Association between covid&#x2010;19 vaccination, SARS&#x2010;CoV&#x2010;2 infection, and risk of immune mediated neurological events: population based cohort and self&#x2010;controlled case series analysis. BMJ. 2022;376:e068373.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8924704</ArticleId><ArticleId IdType="pubmed">35296468</ArticleId></ArticleIdList></Reference><Reference><Citation>Nachamkin I, Shadomy SV, Moran AP, et al. Anti&#x2010;ganglioside antibody induction by swine (A/NJ/1976/H1N1) and other influenza vaccines: insights into vaccine&#x2010;associated Guillain&#x2010;Barr&#xe9; syndrome. J Infect Dis. 2008;198(2):226&#x2010;233.</Citation><ArticleIdList><ArticleId IdType="pubmed">18522505</ArticleId></ArticleIdList></Reference><Reference><Citation>Kadkhoda K. Post&#x2010;adenoviral&#x2010;based vaccines Guillain&#x2010;Barre syndrome: a proposed mechanism. Med Hypotheses. 2022;160:110792.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8837490</ArticleId><ArticleId IdType="pubmed">35185263</ArticleId></ArticleIdList></Reference><Reference><Citation>Pegat A, Vogrig A, Khouri C, Masmoudi K, Vial T, Bernard E. Adenovirus COVID&#x2010;19 vaccines and Guillain&#x2010;Barr&#xe9; syndrome with facial paralysis. Ann Neurol. 2022;91(1):162&#x2010;163.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8652690</ArticleId><ArticleId IdType="pubmed">34699065</ArticleId></ArticleIdList></Reference><Reference><Citation>Almuqrin A, Davidson AD, Williamson MK, et al. SARS&#x2010;CoV&#x2010;2 vaccine ChAdOx1 nCoV&#x2010;19 infection of human cell lines reveals low levels of viral backbone gene transcription alongside very high levels of SARS&#x2010;CoV&#x2010;2 S glycoprotein gene transcription. Genome Med. 2021;13(1):43.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7958140</ArticleId><ArticleId IdType="pubmed">33722288</ArticleId></ArticleIdList></Reference><Reference><Citation>Kowarz E, Krutzke L, K&#xfc;lp M, et al. Vaccine&#x2010;induced COVID&#x2010;19 mimicry syndrome. eLife. 2022;11:e74974.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8846585</ArticleId><ArticleId IdType="pubmed">35084333</ArticleId></ArticleIdList></Reference><Reference><Citation>Colunga Biancatelli RML, Solopov PA, Sharlow ER, Lazo JS, Marik PE, Catravas JD. The SARS&#x2010;CoV&#x2010;2 spike protein subunit S1 induces COVID&#x2010;19&#x2010;like acute lung injury in &#x39a;18&#x2010;hACE2 transgenic mice and barrier dysfunction in human endothelial cells. American J&#xa0;Physiol Lung Cell&#xa0;Mole&#xa0;Physiol. 2021;321:L477&#x2010;L484.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8384477</ArticleId><ArticleId IdType="pubmed">34156871</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim ES, Jeon M&#x2010;T, Kim K&#x2010;S, Lee S, Kim S, Kim D&#x2010;G. Spike proteins of SARS&#x2010;CoV&#x2010;2 induce pathological changes in molecular delivery and metabolic function in the brain endothelial cells. Viruses. 2021;13(10):2021.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8538996</ArticleId><ArticleId IdType="pubmed">34696455</ArticleId></ArticleIdList></Reference><Reference><Citation>Lei Y, Zhang J, Schiavon CR, et al. SARS&#x2010;CoV&#x2010;2 spike protein impairs endothelial function via downregulation of ACE 2. Circ Res. 2021;128(9):1323&#x2010;1326.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8091897</ArticleId><ArticleId IdType="pubmed">33784827</ArticleId></ArticleIdList></Reference><Reference><Citation>Li F, Li J, Wang P&#x2010;H, et al. SARS&#x2010;CoV&#x2010;2 spike promotes inflammation and apoptosis through autophagy by ROS&#x2010;suppressed PI3K/AKT/mTOR signaling. Biochimica et Biophy&#xa0;Acta (BBA). 2021;1867(12):166260.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8390448</ArticleId><ArticleId IdType="pubmed">34461258</ArticleId></ArticleIdList></Reference><Reference><Citation>Nuovo GJ, Magro C, Shaffer T, et al. Endothelial cell damage is the central part of COVID&#x2010;19 and a mouse model induced by injection of the S1 subunit of the spike protein. Ann Diagn Pathol. 2021;51:151682.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7758180</ArticleId><ArticleId IdType="pubmed">33360731</ArticleId></ArticleIdList></Reference><Reference><Citation>Patra T, Meyer K, Geerling L, et al. SARS&#x2010;CoV&#x2010;2 spike protein promotes IL&#x2010;6 trans&#x2010;signaling by activation of angiotensin II receptor signaling in epithelial cells. PLoS Pathog. 2020;16(12):e1009128.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7746263</ArticleId><ArticleId IdType="pubmed">33284859</ArticleId></ArticleIdList></Reference><Reference><Citation>Raghavan S, Kenchappa DB, Leo MD. SARS&#x2010;CoV&#x2010;2 spike protein induces degradation of junctional proteins that maintain endothelial barrier integrity. Front Cardiovasc Med. 2021;8:582.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8225996</ArticleId><ArticleId IdType="pubmed">34179146</ArticleId></ArticleIdList></Reference><Reference><Citation>Rahman M, Irmler M, Keshavan S, et al. Differential effect of SARS&#x2010;CoV&#x2010;2 spike glycoprotein 1 on human bronchial and alveolar lung mucosa models: implications for pathogenicity. Viruses. 2021;13(12):2537.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8708014</ArticleId><ArticleId IdType="pubmed">34960806</ArticleId></ArticleIdList></Reference><Reference><Citation>Edwards KM, Walter AO. TW Post, ed. COVID&#x2010;19: vaccines, 2022.</Citation></Reference><Reference><Citation>Swathy C, Dimachkie MM. TW Post, ed. Guillain&#x2010;Barr&#xe9; syndrome in adults: pathogenesis, clinical features, and diagnosis, 2022.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>